GRDX NASDAQ
GridAI Technologies Corp.
1W: +11.1%
1M: +10.1%
3M: -14.4%
YTD: -25.9%
1Y: -11.2%
3Y: -78.8%
5Y: -100.0%
$3.81
+0.37 (+10.76%)
Weekly Expected Move ±15.4%
$3
$3
$4
$4
$5
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
15 relationships15
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2021-07-27
Earliest Filing
2026-01-07
Latest Filing
target: 8
partner: 5
acquirer: 2
Counterparties (Filed by GRDX)
15 relationshipsCompanies named in GRDX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| ImmunogenX, LLC | — | target | Target entity in the rescission agreement to unwind the prior merger transaction. | 2026-01-07 | View |
| Immuno Corp. | IMVT | target | Former Delaware corporation whose shareholders are parties to the rescission agreement. | 2026-01-07 | View |
| IMMUNO Merger Sub I, Inc. | — | target | Delaware corporation involved in the original merger agreement being rescinded. | 2026-01-07 | View |
| IMMUNO Merger Sub II, LLC | — | target | Delaware limited liability company involved in the original merger agreement being rescinded. | 2026-01-07 | View |
| Access Alternative Group S.A. | — | partner | Consultant appointed to serve as Chief Executive Officer under an amended and restated consulting agreement. | 2025-12-23 | View |
| GridAI Corp | GRDX | target | Target company in a share exchange agreement where Entero Therapeutics acquired 100% of GridAI's outstanding shares. | 2025-10-06 | View |
| ImmunogenX, LLC | — | partner | Counterparty to Amendment to Rescission Agreement regarding unwind of prior merger transactions. | 2025-07-16 | View |
| Immuno Corp. | IMVT | partner | Former parent corporation of ImmunogenX, LLC involved in the rescission agreement. | 2025-07-16 | View |
| Journey Therapeutics, Inc. | — | target | Target of acquisition by Entero Therapeutics, Inc. for 99% of Entero's fully-diluted equity. | 2024-11-13 | View |
| Sanofi | SNYNF | partner | First Wave BioPharma entered into a License Agreement to obtain exclusive worldwide rights to develop and commercialize | 2023-09-14 | View |
| First Wave BioPharma, Inc. | — | target | Defendant in litigation and Buyer in the Merger Agreement. | 2021-11-16 | View |
| AzurRx Biopharma, Inc. | — | acquirer | Entity renamed First Wave BioPharma, Inc. and acting as Buyer in the Merger Agreement. | 2021-11-16 | View |
| First Wave Bio, Inc. | FWBI | target | Target company acquired in a merger agreement entered into on September 13, 2021. | 2021-09-13 | View |
| Alpha Merger Sub, Inc. | — | acquirer | Wholly owned subsidiary of AzurRx BioPharma, Inc. used as the acquiring entity in the merger. | 2021-09-13 | View |
| H.C. Wainwright & Co., LLC | — | partner | Sole book-running manager and underwriter for the common stock offering. | 2021-07-27 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-11 | Material Agreement; Exhibits | Agreement | View |
| 2026-07-23 | Material Agreement; Exhibits | Agreement | View |
| 2026-07-07 | Material Agreement; Unregistered Equity Sales | Agreement | View |
| 2026-07-06 | Material Agreement; Unregistered Equity Sales; Exhibits | Agreement | View |
| 2026-05-20 | Material Agreement; Exhibits | Agreement | View |
| 2026-05-05 | Other Events | View | |
| 2026-04-28 | Delisting Notice; Regulation FD; Exhibits | View | |
| 2026-04-24 | Other Events | View | |
| 2026-04-13 | Exhibits | View | |
| 2026-01-07 | Completion of Acquisition or Disposition of Assets; Financial Statements and Exhibits | Acquisition | View |
| 2025-12-23 | Entry into Material Definitive Agreement; Departure/Election of Directors; Appointment of Officers; | Agreement | View |
| 2025-12-04 | Entry into Material Definitive Agreement; Departure/Election of Directors; Appointment of Officers; | Agreement | View |
| 2025-11-06 | Other Events; Financial Statements and Exhibits | View | |
| 2025-10-31 | Other Events | View | |
| 2025-10-22 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Financial Stateme | Agreement | View |
| 2025-10-06 | Entry into Material Definitive Agreement; Completion of Acquisition or Disposition of Assets; Unregi | Agreement Acquisition | View |
| 2025-09-12 | Entry into Material Definitive Agreement; Departure/Election of Directors; Appointment of Officers; | Agreement | View |
| 2025-09-09 | Termination of Material Definitive Agreement; Departure/Election of Directors; Appointment of Office | View | |
| 2025-08-15 | Material Modification to Rights of Security Holders; Amendments to Articles of Incorporation or Byla | View | |
| 2025-08-11 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Departure/Electio | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR